Transarterial embolization of metastatic mediastinal hepatocellular carcinoma

Chia-Chang Chen, Hong-Zen Yeh, Chi-Sen Chang, Chung-Wang Ko, Han-Chung Lien, Chun-Ying Wu, Siu-Wan Hung

Abstract

This paper introduces an innovative treatment for extrahepatic metastasis of hepatocellular carcinoma. A 71-year-old patient had a stable liver condition following treatment for hepatocellular carcinoma, but later developed symptomatic mediastinal metastasis. This rapidly growing mediastinal mass induced symptoms including cough and hoarseness. Serial sessions of transarterial embolization (TAE) successfully controlled this mediastinal mass with limited side effects. The patient's survival time since the initial diagnosis of the mediastinal hepatocellular carcinoma was 32 mo, significantly longer than the 12 mo mean survival period of patients with similar diagnoses: metastatic hepatocellular carcinoma and a liver condition with a Child-Pugh class A score. Currently, oral sorafenib is the treatment of choice for metastatic hepatocellular carcinoma. Recent studies indicate that locoregional treatment of extrahepatic metastasis of hepatocellular carcinomas might also significantly improve the prognosis in patients with their primary hepatic lesions under control. Many effective locoregional therapies for extrahepatic metastasis, including radiation and surgical resection, may provide palliative effects for hepatocellular carcinoma-associated mediastinal metastasis. This case report demonstrates that TAE of metastatic mediastinal hepatocellular carcinoma provided this patient with tumor control and increased survival time. This finding is important as it can potentially provide an alternative treatment option for patients with similar symptoms and diagnoses.

Key words: Embolization; Hepatocellular carcinoma; Lymphatic metastasis; Endosonography; Mediastinal neoplasm

Chen CC, Yeh HZ, Chang CS, Ko CW, Lien HC, Wu CY, Hung SW. Transarterial embolization of metastatic mediastinal hepatocellular carcinoma. World J Gastroenterol 2013 June 14; 19(22): 3512-3516 Available from: URL: http://www.wjgnet.com/1007-9327/full/v19/i22/3512.htm DOI: http://dx.doi.org/10.3748/wjg.v19.i22.3512
INTRODUCTION
Liver cancer in men is the fifth most frequently diagnosed cancer and the second most frequent cause of cancer death worldwide. In women, it is the seventh most commonly diagnosed cancer and the sixth leading cause of cancer death\(^{[1]}\). Although advances in treatment of hepatocellular carcinoma (HCC) have resulted in prolonged survival of HCC patients, the incidence of extrahepatic metastasis associated with HCC has also risen\(^{[2]}\). Patients with extrahepatic spread have a poor prognosis\(^{[3]}\). Current managements for these patients are oral sorafenib and possibly transarterial chemoembolization (TACE) for the hepatic tumors if the patient has enough remaining liver function\(^{[4]}\). There are few studies examining the efficacy of locoregional management for extrahepatic metastasis. Furthermore, there are even less reports of lymph node-directed therapy in distant lymph node metastasis\(^{[5]}\). In this report, a 71-year-old patient with symptomatic isolated progression of mediastinal lymphadenopathy of HCC was treated with transarterial embolization (TAE). The symptoms were controlled and survival time was longer than expected.

CASE REPORT
A 71-year-old man visited the Taichung Veterans General Hospital for the management of his HCC. His HCC tumor was 3 cm, localized to the right lobe, and diagnosed by elevated α-fetoprotein (AFP) levels and hypervascular appearance on abdominal computer tomography (CT). The patient was a hepatitis B carrier with a class A Child-Pugh score and had early stage HCC as assessed by the Barcelona Clinic Liver Cancer staging classification (stage A). However, this patient did not want to receive curative surgery due to old age and personal preference. He received TACE treatment twice during the first year following his HCC diagnosis. His serum AFP level decreased from 1171 to 14.92 ng/mL following this TACE therapy. One year later, his serum AFP level increased again, but an abdominal CT scan and angiography of the liver did not reveal definite hepatic hypervascular tumors. Two years after the diagnosis of HCC, he started to experience hoarseness due to left vocal cord paralysis. A chest CT scan revealed a 5 cm tumor over the aortopulmonary window of the mediastinum (Figure 1). Metastatic HCC was identified pathologically with endosonography-guided fine needle aspiration. After discussions with the surgeon, radiation oncologist and interventional radiologist, he refused surgery and radiation.

Transarterial embolization of mediastinal tumor was adopted as the treatment modality. Although available now, molecular targeting agents for HCC were not yet a standard care option for patients at that time. The TAE procedure was performed as follows: the first branch of the right superior bronchial artery was identified as the main artery supplying the left hilar metastatic lesion during angiography. Lipiodol was administrated via this artery as the embolizer, and a chest CT scan verified the metastatic lymph nodes were mostly occupied by lipiodol (Figure 2). His AFP level decreased from 17089 to 1061 ng/mL and this TAE session was considered successful. There were no adverse effects like cough, chest pain, fever or dyspnea. Thereafter, he received another four sessions of TAE via several supplying arteries for viable or recurrent components. AFP levels decreased following each successful TAE, but these levels would rebound quickly due to recurrence of the tumor. During the 16-mo follow-up period, his AFP level was approximately 1000-4000 ng/mL. In addition, he began to have night coughs. On the sixth session of TAE, embolization was performed via a small branch of the left branch of internal mammary artery identified by high-resolution chest CT (Figure 3). AFP levels decreased significantly to 16.64 ng/mL and this session was considered successful and the patient remained in stable condition for seven months with no TAE-related complications. However, several months later, the patient began to experience progressive night cough and elevation of AFP levels. A chest CT scan showed progression of mediastinal tumors (Figure 4). A seventh TAE for recurrent mediastinal lymphadenopathy was performed for controlling of tumor. However, his lung condition deteriorated progressively eventually causing him to expire due to pneumonia-related respiratory failure. The patient's survival time since the initial diagnosis of mediastinal metastasis was 32 mo. During the follow up period, his hepatic tumor remained well embolized and his liver function remained stable without evidence of decompensation.

DISCUSSION
The natural course of HCC is unique. Unlike cancers of the colon, breast, lung, and others, whose causes of death are typically due to systemic processes with development of disseminated diseases, HCCs usually present as local lesions and subsequent development of systemic diseases are relatively uncommon\(^{[6]}\). The causes of death from HCC may not only be due to progressive cancer, but may also be due to liver failure.

The prognosis of patients with extrahepatic metastases is usually very poor. The one year and three year survival rates of patients who underwent surgical resection of extrahepatic metastases of HCC was 24% and 7%, respectively. For patients who did not undergo resection, these rates dropped to 8% and 0%, respectively\(^{[7]}\). Poor prognostic factors of extrahepatic metastasis of HCC are poor performance status, a high Child-Pugh score, a large number and size of intrahepatic lesions, the presence of macroscopic vascular invasion, a symptomatic extrahepatic metastasis, and high AFP levels\(^{[8]}\). In this report, the patient exhibited two of these prognostic factors: high AFP level and symptomatic extrahepatic metastasis. He survived for 32 mo following the initial diagnosis of extrahepatic metastasis despite these poor prognostic factors and his decision not to have surgery. The mean survival time for HCC patients with a Child-Pugh class A score and who had developed extrahepatic
metastasis was recently reported to be 12.0 mo\(^6\). Therefore, this patient far exceeded the expected survival time for someone with his diagnosis.

Current management of metastatic HCC is TACE for primary tumor control and possible chemotherapy, radiation or molecular targeting with sorafenib for extrahepatic lesions\(^4\). Some evidence suggests that treatment of extra-hepatic metastasis of HCC can significantly improve the prognosis of patients whose hepatic lesions are under control\(^7\).

Previous studies indicate that surgery for HCC-associated pulmonary\(^9\), adrenal\(^9\) and local lymph node metastasis\(^11\) may be beneficial when added to these traditional treatments. Many effective locoregional therapies for extrahepatic metastasis have also been reported, including irradiation for bone\(^12\), lymph node\(^13\), brain\(^14\) and adrenal\(^15\) metastases, and percutaneous ablation for adrenal\(^16\) and bone metastases\(^17\). Further, TAE has been used as a therapy for adrenal metastasis\(^18\) while this is the first report of TAE for mediastinal metastasis.

The most common sites of lymph node metastasis of HCC are locoregional lymph nodes including paraaortic,
portohepatic, periceliac and peripancreatic nodes. The most common site of HCC-associated distant metastatic lymphadenopathy is the mediastinal lymph nodes[19]. Because lymph node metastasis or dissemination itself is not the usual cause of death[5], there are relatively few studies examining the management of metastatic lymph nodes. Lymph node metastases that cause agonizing pain, or rarely life-threatening conditions like pericardial or esophageal invasion[20], may be indications for locoregional treatment such as radiotherapy or surgical resection.

Excellent radiotherapy responsiveness was reported in patients whose intrahepatic HCC was concurrently under control[13]. However, radiation at the mediastinum is associated with cardiovascular toxicity, which may present with acute pericarditis, restrict cardiomyopathy, ischemic heart disease, congestive heart failure and valvular heart disease[21]. Moreover, radiation therapy at the mediastinum is also associated with a 5%-10% risk of symptomatic radiation pneumonitis[22]. Subtle lung function impairment induced by radiation injury may further reduce the capacity of a patient to deal with future cardiopulmonary stress. Surgical resection may be an option if the patient has good liver function and isolated lymph node metastasis[23]. However, the existence of possible occult metastasis and the variable degree of hepatic decompensation in HCC patients greatly reduce the benefits of surgery.

Currently, the mainstay treatment for metastatic HCC is sorafenib[4], while options including heavy ion or proton radiotherapy also remain. TAE for mediastinal metastatic HCC may be an alternative option for certain patients with localized metastatic lymph nodes. Furthermore, TAE does not cost more than the other treatment modalities. In this report, the patient did not present significant side effects during several sessions of TAE and had satisfactory control of his tumor. However, several challenges associated with performing TAE in the mediastinum remain including: the considerable challenge of locating the supplying vessels, the close proximity to many critical arteries in this part of the body such as the spinal cord artery, and the risk of reflux of embolizer to other vital areas. Above all, the key challenge to providing a safe and successful TAE is selection of the supplying artery. Thus, it remains unclear whether this technique can be widely used.

In conclusion, this report showed that the use of TAE for treatment of a metastatic mediastinal HCC provided temporal tumor control and increased survival time. In the right environment, TAE should be an alternative option for well-selected patients with mediastinal metastasis of HCC.

REFERENCES

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Kanda M, Tateishi R, Yoshida H, Sato T, Masuzaki R, Ohki T, Imamura J, Goto T, Yoshida H, Hamamura K, Ohi S, Kanai F, Shiina S, Omata M. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int 2008; 28: 1256-1263 [PMID: 18710423 DOI: 10.1111/j.1478-3231.2008.01864.x]
3. Natsuizaka M, Omura T, Akaike T, Kuwata Y, Yamazaki K, Sato T, Karino Y, Toyota J, Suga T, Asaka M. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol 2005; 20: 1781-1787 [PMID: 16246200 DOI: 10.1111/j.1440-1746.2005.03919.x]
4. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;
TAE of mediastinal HCC

Chen CC et al. J Gastroenterol Hepatol 2007; 22: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMoa1001683]

Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, Hirama A, Kodama H, Takahashi S, Chayama K. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007; 13: 414-420 [PMID: 17230611]

Senthilnathan S, Memom K, Lewandowski RJ, Kulik L, Mulcahy MF, Riaz A, Miller FH, Yagihashi V, Nikolaidis P, Wang E, Baker T, Abecassis M, Benson AB, Omary RA, Salem R. Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients. Hepatology 2012; 55: 1432-1442 [PMID: 22109811 DOI: 10.1002/hep.24812]

Chan KM, Yu MC, Wu TJ, Lee CF, Chen TC, Lee WC, Chen MF. Efficacy of surgical resection in management of isolated extrahepatic metastases of hepatocellular carcinoma. World J Gastroenterol 2009; 15: 5481-5488 [PMID: 19916180 DOI: 10.3748/wjg.15.5481]

Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H, Koike K. Hepatocellular carcinoma with extrapleural metastasis: clinical features and prognostic factors. Cancer 2011; 117: 4475-4483 [PMID: 21437884 DOI: 10.1002/cncr.25960]

Lam CM, Lo CM, Yuen WK, Liu CL, Fan ST. Prolonged survival in selected patients following surgical resection for pulmonary metastasis from hepatocellular carcinoma. Br J Surg 1998; 85: 1198-1200 [PMID: 9752858 DOI: 10.1046/j.1365-2168.1998.00846.x]

Park JS, Yoon DS, Kim KS, Choi JS, Lee WJ, Chi HS, Kim BR. What is the best treatment modality for adrenal metastasis from hepatocellular carcinoma? J Surg Oncol 2007; 96: 32-36 [PMID: 17345960 DOI: 10.1002/jso.20773]

Une Y, Misawa K, Shimamura T, Ogawara K, Masuko Y, Sato N, Nakajima Y, Uchino J. Treatment of lymph node recurrence in patients with hepatocellular carcinoma. Surg Today 1994; 24: 606-609 [PMID: 7949768 DOI: 10.1007/BF01833724]

Kazui T, Karasawa K, Tanaka Y, Matuda T, Kurosaki H, Tanaka S, Kuzamaki T. Radiotherapy for osseus metastases from hepatocellular carcinoma: a retrospective study of 57 patients. Am J Gastroenterol 1998; 93: 2167-2171 [PMID: 9820391 DOI: 10.1111/j.1572-0241.1998.0014.x]

Park YJ, Lim do H, Paik SW, Koh KC, Lee JH, Choi MS, Yoo BC, Nam HR, Oh DR, Park W, Ahn YC, Huh SJ. Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Gastroenterol 2006; 41: 1099-1106 [PMID: 17160521 DOI: 10.1007/s00535-006-1895-x]

Chang L, Chen YL, Kao MC. Intracranial metastasis of hepatocellular carcinoma: review of 45 cases. Surg Neurol 2004; 62: 172-177 [PMID: 15261518 DOI: 10.1016/j.surneu.2003.10.002]

Zeng ZC, Tang ZY, Fan J, Zhou J, Qin LX, Ye SL, Sun HC, Wang BL, Zhang JY, Yu Y, Cheng JM, Wang XL, Guo W. Radiation therapy for adrenal gland metastases from hepatocellular carcinoma. Jpn J Clin Oncol 2005; 35: 61-67 [PMID: 15709083 DOI: 10.1093/jjc/jhy020]

Kashima M, Yamakado K, Takaki H, Kaminou T, Tanigawa N, Nakatsuka A, Takeda K. Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma. AJR Am J Roentgenol 2010; 194: 536-541 [PMID: 20093621 DOI: 10.2214/AJR.09.2975]

Yamakado K, Anai H, Takaki H, Sakaguchi H, Tanaka T, Kichikawa K, Takeda K. Adrenal metastasis from hepatocellular carcinoma: radiofrequency ablation combined with adrenal arterial chemoembolization in six patients. AJR Am J Roentgenol 2009; 192: W300-W305 [PMID: 19457793 DOI: 10.2214/AJR.08.1752]

Kuehl H, Statteaus J, Forsting M, Antoch G. Transhepatic CT-guided radiofrequency ablation of adrenal metastases from hepatocellular carcinoma. Cardiovasc Intervent Radiol 2008; 31: 1210-1214 [PMID: 18584241 DOI: 10.1007/s00270-008-9377-6]

Katyal S, Oliver JH, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000; 216: 698-703 [PMID: 10966997]

Huang CC, Ng WQ, Chiang JH, Chen FH, Huang CH, Wang YJ, Chang FY, Lee SD. Hepatocellular carcinoma with mediastinal and pericardial invasion: report of two cases. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62: 891-895 [PMID: 10634004]

Gagliardi G, Constine LS, Moiseenko V, Correa C, Pierce LJ, Allen AM, Marks LB. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010; 76: 577-585 [PMID: 20171522 DOI: 10.1016/j.ijrobp.2009.04.093]

Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV, Timmerman RD, Martel MK, Jackson A. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010; 76: 577-585 [PMID: 20171522 DOI: 10.1016/j.ijrobp.2009.06.091]

Chua TC, Morris DL. Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. Surg Oncol 2012; 21: 95-101 [PMID: 21397495 DOI: 10.1016/j.suronc.2011.01.005]

P-Reviewers Enjoji M, Ferraioli G, Ramia JM, Tsuchiya A
S-Editor Huang XZ L-Editor A E-Editor Xiong L